Rapid Micro BiosystemsRPID
About: Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
Employees: 163
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
0% more funds holding
Funds holding: 19 [Q3] → 19 (+0) [Q4]
15.02% less ownership
Funds ownership: 46.69% [Q3] → 31.67% (-15.02%) [Q4]
31% less capital invested
Capital invested by funds: $15.6M [Q3] → $10.8M (-$4.87M) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for RPID.
Financial journalist opinion
Based on 4 articles about RPID published over the past 30 days









